Publication: The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo.
Loading...
Identifiers
Date
2022-03-26
Authors
Beltran-Camacho, Lucia
Eslava-Alcon, Sara
Rojas-Torres, Marta
Sanchez-Morillo, Daniel
Martinez-Nicolas, Mª Pilar
Martin-Bermejo, Victoria
de la Torre, Ines Garcia
Berrocoso, Esther
Moreno, Juan Antonio
Moreno-Luna, Rafael
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ Group
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already caused 6 million deaths worldwide. While asymptomatic individuals are responsible of many potential transmissions, the difficulty to identify and isolate them at the high peak of infection constitutes still a real challenge. Moreover, SARS-CoV-2 provokes severe vascular damage and thromboembolic events in critical COVID-19 patients, deriving in many related deaths and long-hauler symptoms. Understanding how these processes are triggered as well as the potential long-term sequelae, even in asymptomatic individuals, becomes essential. We have evaluated, by application of a proteomics-based quantitative approach, the effect of serum from COVID-19 asymptomatic individuals over circulating angiogenic cells (CACs). Healthy CACs were incubated ex-vivo with the serum of either COVID-19 negative (PCR -/IgG -, n:8) or COVID-19 positive asymptomatic donors, at different infective stages: PCR +/IgG - (n:8) and PCR -/IgG + (n:8). Also, a label free quantitative approach was applied to identify and quantify protein differences between these serums. Finally, machine learning algorithms were applied to validate the differential protein patterns in CACs. Our results confirmed that SARS-CoV-2 promotes changes at the protein level in the serum of infected asymptomatic individuals, mainly correlated with altered coagulation and inflammatory processes (Fibrinogen, Von Willebrand Factor, Thrombospondin-1). At the cellular level, proteins like ICAM-1, TLR2 or Ezrin/Radixin were only up-regulated in CACs treated with the serum of asymptomatic patients at the highest peak of infection (PCR + /IgG -), but not with the serum of PCR -/IgG + individuals. Several proteins stood out as significantly discriminating markers in CACs in response to PCR or IgG + serums. Many of these proteins particiArticle title: Kindly check and confirm the edit made in the article title.pate in the initial endothelial response against the virus. The ex vivo incubation of CACs with the serum of asymptomatic COVID-19 donors at different stages of infection promoted protein changes representative of the endothelial dysfunction and inflammatory response after viral infection, together with activation of the coagulation process. The current approach constitutes an optimal model to study the response of vascular cells to SARS-CoV-2 infection, and an alternative platform to test potential inhibitors targeting either the virus entry pathway or the immune responses following SARS-CoV-2 infection.
Description
MeSH Terms
COVID-19
Humans
Immunoglobulin G
Nucleic acid amplification techniques
SARS-CoV-2
Humans
Immunoglobulin G
Nucleic acid amplification techniques
SARS-CoV-2
DeCS Terms
Humanos
Inmunoglobulina G
Técnicas de amplificación de ácido nucleico
Inmunoglobulina G
Técnicas de amplificación de ácido nucleico
CIE Terms
Keywords
Asymptomatic, COVID-19, Circulating angiogenic cells, Endothelial dysfunction, Endothelial progenitor cells, Proteomics, SARS-CoV-2
Citation
Beltrán-Camacho L, Eslava-Alcón S, Rojas-Torres M, Sánchez-Morillo D, Martinez-Nicolás MP, Martín-Bermejo V, et al. The serum of COVID-19 asymptomatic patients up-regulates proteins related to endothelial dysfunction and viral response in circulating angiogenic cells ex-vivo. Mol Med. 2022 Apr 9;28(1):40